

Steven K Grinspoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5428962/publications.pdf>

Version: 2024-02-01

136
papers

9,955
citations

41344

49
h-index

34986

98
g-index

136
all docs

136
docs citations

136
times ranked

7751
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2506-2512.	3.6	1,404
2	Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. <i>Clinical Infectious Diseases</i> , 2001, 32, 130-139.	5.8	639
3	Arterial Inflammation in Patients With HIV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 379.	7.4	411
4	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e98-e124.	1.6	376
5	Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 1227-1236.	4.0	374
6	Effects of Recombinant Human IGF-I and Oral Contraceptive Administration on Bone Density in Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2883-2891.	3.6	316
7	Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 268-273.	2.1	310
8	Metformin in the Treatment of HIV Lipodystrophy Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 472-7.	7.4	289
9	Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. <i>Aids</i> , 2010, 24, 243-253.	2.2	287
10	Measurement of Arterial Activity on Routine FDG PET/CT Images Improves Prediction of Risk of Future CV Events. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 1250-1259.	5.3	273
11	Metabolic Effects of Rosiglitazone in HIV Lipodystrophy. <i>Annals of Internal Medicine</i> , 2004, 140, 786.	3.9	195
12	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2015, 2, e52-e63.	4.7	188
13	Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2013, 208, 1737-1746.	4.0	185
14	Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. <i>Aids</i> , 2012, 26, 2409-2412.	2.2	177
15	Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2000, 28, 284-292.	4.0	168
16	Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. <i>New England Journal of Medicine</i> , 2007, 357, 2359-2370.	27.0	168
17	Elevated Levels of Monocyte Activation Markers Are Associated With Subclinical Atherosclerosis in Men With and Those Without HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 1219-1228.	4.0	159
18	Inflammation, immune activation, and cardiovascular disease in HIV. <i>Aids</i> , 2016, 30, 1495-1509.	2.2	152

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. <i>Circulation</i> , 2018, 137, 2203-2214.	1.6	151
20	Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 615-619.	2.1	148
21	Weight Loss and Wasting in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2003, 36, S69-S78.	5.8	147
22	Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 504-510.	3.6	145
23	Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution. <i>Clinical Infectious Diseases</i> , 2003, 36, 909-916.	5.8	120
24	Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. <i>Aids</i> , 2013, 27, 1263-1272.	2.2	115
25	The Effects of Central Adiposity on Growth Hormone (GH) Response to GH-Releasing Hormone-Arginine Stimulation Testing in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4254-4260.	3.6	105
26	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	2.7	99
27	Risk of coronary heart disease in patients with HIV infection. <i>Nature Reviews Cardiology</i> , 2014, 11, 728-741.	13.7	90
28	Sustained Benefits of Metformin Therapy on Markers of Cardiovascular Risk in Human Immunodeficiency Virus-Infected Patients with Fat Redistribution and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4611-4615.	3.6	88
29	Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 509.	7.4	80
30	Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4291-4304.	3.6	77
31	RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2873-2882.	3.6	75
32	Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. <i>Aids</i> , 2017, 31, 797-806.	2.2	74
33	Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. <i>Aids</i> , 2012, 26, 587-597.	2.2	73
34	Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 380.	7.4	70
35	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. <i>Topics in Antiviral Medicine</i> , 2015, 23, 146-9.	0.1	70
36	Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 164-171.	2.1	66

#	ARTICLE	IF	CITATIONS
37	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2016, 1, 474.	6.1	66
38	Pathophysiology and management of cardiovascular disease in patients with HIV. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 598-610.	11.4	66
39	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. <i>Aids</i> , 2014, 28, 2061-2070.	2.2	65
40	Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 420-431.	4.0	64
41	Mechanisms of Androgen Deficiency in Human Immunodeficiency Virus-Infected Women with the Wasting Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4120-4126.	3.6	62
42	Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. <i>Aids</i> , 2015, 29, 443-452.	2.2	60
43	Unraveling Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1403-1412.	2.8	59
44	Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 174-184.	2.1	56
45	Mechanisms and Strategies for Insulin Resistance in Acquired Immune Deficiency Syndrome. <i>Clinical Infectious Diseases</i> , 2003, 37, S85-S90.	5.8	54
46	Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu117.	0.9	54
47	Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women. <i>Menopause</i> , 2014, 21, 403-409.	2.0	52
48	Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. <i>Aids</i> , 2010, 24, 2127-2130.	2.2	51
49	Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. <i>Neurology</i> , 2014, 83, 1705-1711.	1.1	51
50	Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004043.	2.6	50
51	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. <i>Lancet HIV</i> , 2019, 6, e821-e830.	4.7	50
52	Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. <i>The American Journal of Medicine: Supplement</i> , 2005, 118, 23-28.	1.6	49
53	Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. <i>Aids</i> , 2016, 30, 583-590.	2.2	45
54	Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 150-158.	3.6	43

#	ARTICLE	IF	CITATIONS
55	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	2.7	43
56	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e520-e533.	3.6	43
57	Effects of Estrogen and Recombinant Human Insulin-Like Growth Factor-I on Ghrelin Secretion in Severe Undernutrition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3988-3993.	3.6	42
58	Dysfunctional Subcutaneous Fat With Reduced Dicer and Brown Adipose Tissue Gene Expression in HIV-Infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1225-1234.	3.6	39
59	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. <i>JAMA Network Open</i> , 2021, 4, e2114923.	5.9	38
60	Epidemiology of ischemic heart disease in HIV. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 540-547.	3.8	35
61	Deiodinase 2 Expression Is Increased in Dorsocervical Fat of Patients with HIV-Associated Lipohypertrophy Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E602-E607.	3.6	29
62	Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu076.	0.9	29
63	Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. <i>Journal of Infectious Diseases</i> , 2020, 222, S1-S7.	4.0	28
64	Effects of aging and smoking on carotid intima-media thickness in HIV-infection. <i>Aids</i> , 2013, 27, 49-57.	2.2	26
65	Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin. <i>Clinical Infectious Diseases</i> , 2012, 54, 1642-1651.	5.8	25
66	Benefits and Risks of Statin Therapy in the HIV-Infected Population. <i>Current Infectious Disease Reports</i> , 2018, 20, 20.	3.0	25
67	Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. <i>Clinical Endocrinology</i> , 2015, 82, 678-685.	2.4	24
68	Amygdalar activity predicts future incident diabetes independently of adiposity. <i>Psychoneuroendocrinology</i> , 2019, 100, 32-40.	2.7	24
69	High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity Is Improved by Treatment With Antiretroviral Therapy in Acute Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu108.	0.9	23
70	Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4176-4186.	3.6	23
71	Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. <i>Journal of Infectious Diseases</i> , 2020, 222, S52-S62.	4.0	22
72	Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	20

#	ARTICLE	IF	CITATIONS
73	Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2376-2384.	3.6	20
74	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1762-1775.	2.4	20
75	Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1123-1133.	3.6	19
76	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	5.8	19
77	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.9	19
78	Increased aldosterone among HIV-infected women with visceral fat accumulation. <i>Aids</i> , 2009, 23, 2366-2370.	2.2	17
79	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	4.0	17
80	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. <i>Antiviral Therapy</i> , 2014, 19, 805-811.	1.0	16
81	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. <i>EBioMedicine</i> , 2018, 35, 58-66.	6.1	16
82	Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S20-S30.	4.0	16
83	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. <i>Journal of Infectious Diseases</i> , 2020, 222, 929-939.	4.0	16
84	Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices During HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1336-1340.	4.0	15
85	Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1029-1038.	3.6	15
86	Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 2087-2094.	5.8	15
87	Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity. <i>Growth Hormone and IGF Research</i> , 2014, 24, 10-15.	1.1	14
88	Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. <i>HIV Clinical Trials</i> , 2017, 18, 83-91.	2.0	14
89	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 105-110.	2.1	14
90	Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. <i>Nutrition and Diabetes</i> , 2019, 9, 6.	3.2	13

#	ARTICLE	IF	CITATIONS
91	Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020, 5, .	5.0	13
92	The past 10 yearsâ€™ new hormones, new functions, new endocrine organs. Nature Reviews Endocrinology, 2015, 11, 681-686.	9.6	12
93	Mechanisms of Androgen Deficiency in Human Immunodeficiency Virus-Infected Women with the Wasting Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4120-4126.	3.6	12
94	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. Journal of Infectious Diseases, 2022, 226, 1809-1822.	4.0	11
95	Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2016, 3, ofw062.	0.9	10
96	Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1558-1565.	3.6	10
97	A neurobiological link between transportation noise exposure and metabolic disease in humans. Psychoneuroendocrinology, 2021, 131, 105331.	2.7	10
98	Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. JCI Insight, 2021, 6, .	5.0	10
99	Approach to the Patient With Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1714-1726.	3.6	10
100	Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiological Reports, 2017, 5, e13386.	1.7	9
101	Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. Aids, 2017, 31, 2253-2259.	2.2	9
102	Novel mediators of statin effects on plaque in HIV. Aids, 2018, 32, 867-876.	2.2	9
103	Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV. Journal of Cardiovascular Computed Tomography, 2020, 14, 144-148.	1.3	9
104	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity, 2020, 28, 749-755.	3.0	9
105	Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation. Journal of the Endocrine Society, 2018, 2, 1147-1157.	0.2	8
106	Association of In Utero HIV Exposure With Obesity and Reactive Airway Disease in HIV-Negative Adolescents and Young Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 126-134.	2.1	8
107	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S8-S19.	4.0	8
108	NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS. Transactions of the American Clinical and Climatological Association, 2018, 129, 140-154.	0.5	8

#	ARTICLE	IF	CITATIONS
109	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	4.0	8
110	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2022, 75, 1324-1333.	5.8	8
111	Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy326.	0.9	7
112	Serum Lipocalin 2 (Neutrophil Gelatinase-Associated Lipocalin) in Relation to Biomarkers of Inflammation and Cardiac Stretch During Activation of the Renin-Angiotensin-Aldosterone System in Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2019, 220, 1420-1424.	4.0	6
113	Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa459.	0.9	6
114	Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. <i>Scientific Reports</i> , 2021, 11, 10485.	3.3	6
115	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , 2020, 21, 11-23.	1.1	5
116	Regional Osteoporosis in Anorexia Nervosa. <i>Annals of Internal Medicine</i> , 2001, 135, 844.	3.9	4
117	Cardiovascular Disease Imaging in HIV. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	4
118	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. <i>Journal of Infectious Diseases</i> , 2020, 222, S31-S40.	4.0	4
119	Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. <i>Clinical Infectious Diseases</i> , 2022, 75, 1154-1163.	5.8	4
120	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 349-359.	2.1	4
121	Acute hyperinsulinemia effects on systemic markers of immune activation in HIV. <i>Aids</i> , 2017, 31, 1771-1773.	2.2	3
122	Myocardial Dysfunction With Contemporary Management of HIV. <i>JACC: Heart Failure</i> , 2019, 7, 109-111.	4.1	3
123	Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3398-3412.	3.6	3
124	Tesamorelin improves fat quality independent of changes in fat quantity. <i>Aids</i> , 2021, 35, 1395-1402.	2.2	3
125	Epicardial adipose tissue and atherogenesis. <i>Aids</i> , 2014, 28, 1679-1681.	2.2	2
126	AIDS: Endocrinologic and Metabolic Considerations. <i>Annals of Medicine</i> , 1994, 26, 321-323.	3.8	1

#	ARTICLE	IF	CITATIONS
127	Testosterone and Resistance Training in AIDS. <i>Annals of Internal Medicine</i> , 2001, 135, 65.	3.9	1
128	An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, S41-S51.	4.0	1
129	A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. <i>Viruses</i> , 2021, 13, 2135.	3.3	1
130	Endocrinology of HIV/AIDS. , 2016, , 1776-1798.		1
131	Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab175.	0.2	1
132	Rosiglitazone for Treatment of HIV Lipodystrophy. <i>Annals of Internal Medicine</i> , 2004, 141, 739.	3.9	0
133	HIV-associated dyslipidemia: the Heart Positive study. <i>Nature Reviews Endocrinology</i> , 2011, 7, 443-444.	9.6	0
134	Reply to Maurice and Lemoine. <i>Clinical Infectious Diseases</i> , 2021, 72, 909-909.	5.8	0
135	Abstract 15567: Increased Visceral Fat Volume is Associated With Aortic Inflammation and Cardiovascular Events. <i>Circulation</i> , 2015, 132, .	1.6	0
136	SAT-256 Obesity and Reactive Airway Disease Are Increased Among HIV-Exposed Uninfected Adolescents. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0